Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study - Hellmann, M D; Rizvi, N A; Goldman, J W (Lancet Oncol, 2017)
et al.